Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NYSE:MNK
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.07 billion
  • Outstanding Shares: 99,346,000
Average Prices:
  • 50 Day Moving Avg: $44.48
  • 200 Day Moving Avg: $49.69
  • 52 Week Range: $38.81 - $85.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.86
  • P/E Growth: 0.95
Sales & Book Value:
  • Annual Revenue: $3.31 billion
  • Price / Sales: 1.23
  • Book Value: $51.45 per share
  • Price / Book: 0.80
  • EBIDTA: $744.3 million
  • Net Margins: 7.75%
  • Return on Equity: 17.34%
  • Return on Assets: 5.71%
  • Debt-to-Equity Ratio: 1.18%
  • Current Ratio: 1.20%
  • Quick Ratio: 0.93%
  • Average Volume: 1.88 million shs.
  • Beta: 1.48
  • Short Ratio: 8.68

Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt PLC's stock buyback program work?

Mallinckrodt PLC announced that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 18.5% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

How were Mallinckrodt PLC's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) released its quarterly earnings results on Monday, May, 8th. The company reported $1.68 EPS for the quarter, topping the Zacks' consensus estimate of $1.63 by $0.05. The firm earned $810.90 million during the quarter, compared to analysts' expectations of $781.23 million. Mallinckrodt PLC had a return on equity of 17.34% and a net margin of 7.75%. The business's revenue for the quarter was down .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.01 earnings per share. View Mallinckrodt PLC's Earnings History.

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

16 analysts have issued 12 month price objectives for Mallinckrodt PLC's shares. Their forecasts range from $60.00 to $98.00. On average, they expect Mallinckrodt PLC's stock price to reach $78.91 in the next year. View Analyst Ratings for Mallinckrodt PLC.

What are analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt reported strong results for the transition quarter (Oct 1 to Dec 30) beating both sales and earnings expectations. The results were driven by volume-based growth across its Specialty Brands segment which once more offset the ongoing challenges in Specialty Generics segment. Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also announced to sell its Intrathecal Therapy business. Meanwhile, Mallinckrodt acquire-to-invest policy is apparently paying off as both Inomax and Therakos continue to witness solid demand along with Ofirmev. The performance of Acthar has been impressive too. Estimates for 2017 have gone up post the strong results. However, shares have underperformed the Medical-Generic Drugs industry in 2017." (2/9/2017)
  • 2. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
  • 3. Mizuho analysts commented, "Yesterday MNK sold off based on headlines of an FTC anti-trust investigation, then rebounded quickly after a $100M settlement was announced. This settlement was related to legacy Synacthen issues associated with its Questcor acquisition. The stock then plunged again on more detailed news that Mallinckrodt would need to license two Synacthen indications (infantile spasms and nephrotic syndrome) to an undisclosed company. Investors were concerned that this could introduce additional competition to Acthar and create yet another overhang on the stock. Management held a call this morning that, in our view, dispelled most if not all of these concerns as outlined below. We reiterate our Buy rating on the stock and expect a rebound." (1/19/2017)

Who are some of Mallinckrodt PLC's key competitors?

Who owns Mallinckrodt PLC stock?

Mallinckrodt PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.79%), BlackRock Inc. (8.34%), Paulson & CO. Inc. (7.55%), State Street Corp (5.23%), Alliancebernstein L.P. (2.77%) and Prudential Financial Inc. (1.85%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.

Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Janus Capital Management LLC, Morgan Stanley, Paulson & CO. Inc., Cornerstone Capital Management Holdings LLC., JPMorgan Chase & Co., FMR LLC and Westpac Banking Corp. View Insider Buying and Selling for Mallinckrodt PLC.

Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Alliancebernstein L.P., Hotchkis & Wiley Capital Management LLC, Bank of America Corp DE, Legal & General Group Plc, Ameriprise Financial Inc., State Street Corp and Acadian Asset Management LLC. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mallinckrodt PLC stock cost?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $41.00.

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (?)
Ratings Breakdown: 2 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $78.91 (92.45% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017BMO Capital MarketsLower Price TargetOutperform$79.00 -> $69.00MediumView Rating Details
5/9/2017Canaccord GenuityLower Price TargetBuy -> Buy$91.00 -> $87.00MediumView Rating Details
4/21/2017Jefferies Group LLCReiterated RatingBuy$70.00HighView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
2/8/2017Piper Jaffray CompaniesLower Price TargetOverweight$108.00 -> $83.00N/AView Rating Details
2/3/2017MizuhoLower Price TargetBuy$85.00 -> $69.00N/AView Rating Details
1/25/2017JPMorgan Chase & Co.Set Price TargetHold$78.00N/AView Rating Details
1/19/2017Oppenheimer Holdings Inc.Set Price TargetBuy$72.00N/AView Rating Details
1/19/2017Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
11/30/2016Deutsche Bank AGLower Price TargetBuy$78.00 -> $73.00N/AView Rating Details
11/18/2016Raymond James Financial, Inc.Initiated CoverageOutperform$72.00N/AView Rating Details
9/21/2016Morgan StanleyReiterated RatingBuy$82.00N/AView Rating Details
8/26/2016Goldman Sachs Group IncReiterated RatingNeutral$83.00N/AView Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00N/AView Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
10/7/2015Bank of America CorpLower Price TargetBuy$135.00 -> $131.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)
Earnings History by Quarter for Mallinckrodt PLC (NYSE:MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.58
2018 EPS Consensus Estimate: $8.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.81
Q3 20173$1.88$1.96$1.91
Q4 20173$2.02$2.35$2.16
Q1 20183$1.82$2.06$1.93
Q2 20181$2.09$2.09$2.09
Q3 20181$2.03$2.03$2.03
Q4 20181$2.48$2.48$2.48
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 88.79%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline logoMallinckrodt (MNK) Confirms First Patient Enrolled in Mallinckrodt Phase 4 Trial of HP Acthar® Gel (Repository ... - - May 24 at 10:40 AM logoOversold Conditions For Mallinckrodt (MNK) - May 23 at 6:09 PM logoFirst Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse - May 23 at 6:09 PM logoMallinckrodt & Express Scripts: What Chanos Got Wrong - May 22 at 10:06 AM logoJim Chanos is shorting 2 drug stocks with a 'murky alliance' - May 20 at 6:15 PM logoShort-seller criticizes 'murky alliance' between Mallinckrodt, Express Scripts - May 19 at 7:01 PM logoMallinckrodt Rejects Jim Chanos Thesis: 'Misleading, Not Based On Fact' - May 19 at 11:07 AM logoTwo More Stock Picks From Hedge Fund Leaders at SALT - May 19 at 11:07 AM logo[$$] Jim Chanos Predicts Stock Drop for Mallinckrodt - May 19 at 11:07 AM logoJim Chanos has a way to profit on the drug overpricing backlash and still hates Tesla - May 19 at 11:07 AM logoInsider Buying: Mallinckrodt PLC (MNK) VP Acquires 1,968 Shares of Stock - May 15 at 11:40 AM logoMallinckrodt PLC (MNK) Given Consensus Rating of "Buy" by Brokerages - May 15 at 10:52 AM logoMallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare Conference - May 12 at 7:12 PM logoAnalysts Issue Forecasts for Mallinckrodt PLC's Q2 2017 Earnings (MNK) - May 11 at 8:12 AM logoJefferies Group Comments on Mallinckrodt PLC's Q2 2017 Earnings (MNK) - May 11 at 8:12 AM logoMallinckrodt PLC's (MNK) Outperform Rating Reiterated at BMO Capital Markets - May 10 at 10:02 PM logoMallinckrodt plc (MNK) PT Lowered to $69 at BMO Capital Following 1Q In-Line EPS; 'Upside in Generics May Not be ... - - May 10 at 6:41 PM logoEarnings Reaction History: Mallinckrodt plc, 45.5% Follow-Through Indicator, 5.7% Sensitive - Nasdaq - May 10 at 12:20 PM logoQ3 2017 EPS Estimates for Mallinckrodt PLC Raised by Oppenheimer Holdings (MNK) - May 10 at 9:06 AM logoMallinckrodt PLC to Post Q3 2017 Earnings of $1.89 Per Share, Jefferies Group Forecasts (MNK) - May 10 at 9:06 AM logoMallinckrodt Plc – Value Analysis (NYSE:MNK) : May 9, 2017 - May 9 at 6:17 PM logoEdited Transcript of MNK earnings conference call or presentation 8-May-17 12:30pm GMT - May 9 at 11:44 AM logoMallinckrodt PLC (MNK) Price Target Cut to $87.00 - May 9 at 11:32 AM logoMallinckrodt (MNK) Tops Q1 Earnings, Sales - May 8 at 6:09 PM logoMallinckrodt Earnings, Revenues Beat Estimates in Q1 - May 8 at 6:09 PM logoMallinckrodt PLC (MNK) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - May 8 at 4:58 PM logoForm 8-K Mallinckrodt plc For: May 08 - May 8 at 12:33 PM logoMallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017 - May 8 at 12:33 PM logoMallinckrodt tops Street 1Q forecasts - May 8 at 12:33 PM logoMallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : May 8, 2017 - May 8 at 12:33 PM logoMallinckrodt's stock jumps after profit and sales beat - May 8 at 12:33 PM logoJefferies Group Brokers Boost Earnings Estimates for Mallinckrodt PLC (MNK) - May 8 at 8:27 AM logoMallinckrodt (MNK) Says First Patient Enrolled in Phase 2 Trial of StrataGraft Regenerative Skin Tissue - May 6 at 6:32 PM logoAvoid Mallinckrodt Into Earnings - Seeking Alpha - May 5 at 11:53 PM logoMallinckrodt (MNK) Says First Patient Enrolled in Phase 2 Trial of StrataGraft Regenerative Skin Tissue - - May 4 at 11:40 PM logoMallinckrodt PLC (MNK) Receives Media Sentiment Score of -0.02 - May 4 at 7:24 PM logoFirst Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin Tissue - May 4 at 6:40 PM logoWhat's in Store for Mallinckrodt (MNK) This Earnings Season? - May 3 at 10:40 PM logoMallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis Therapy - PR Newswire (press release) - May 3 at 5:39 PM logoWhat's in Store for Mallinckrodt (MNK) This Earnings Season? - May 3 at 5:39 PM logoMallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis Therapy - May 3 at 10:49 AM logoZacks: Analysts Anticipate Mallinckrodt PLC (MNK) to Post $1.64 EPS - May 2 at 7:36 AM logoSomewhat Positive Press Coverage Likely to Impact Mallinckrodt PLC (MNK) Stock Price - April 30 at 5:21 PM logoMallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Annual Meeting - April 28 at 9:13 AM logoAgree To Buy Mallinckrodt At $30, Earn 8.3% Using Options - April 27 at 7:09 PM logoMallinckrodt PLC (MNK) Earns Daily Media Sentiment Rating of 0.19 - April 27 at 3:28 PM logoMallinckrodt To Present At UBS Global Healthcare Conference - April 24 at 6:51 PM logoPositive News Coverage Somewhat Likely to Affect Mallinckrodt PLC (MNK) Stock Price - April 24 at 4:32 PM logoOppenheimer Holdings Comments on Mallinckrodt PLC's Q2 2017 Earnings (MNK) - April 24 at 7:56 AM logoMallinckrodt PLC (MNK) Receives "Buy" Rating from Jefferies Group LLC - April 22 at 6:32 PM



Mallinckrodt PLC (MNK) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff